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Abstract This study investigates motor (MNCS) and sensory (SNCS) nerve conduction
in a sample of non-diabetic obese people without symptoms suggestive of neuropathy and
looks for a possible metabolic alteration. Twenty-one patients and 20 age-matched con-
trols underwent (a) MNCS (median, ulnar, peroneal, and tibial) and SNCS (median, ulnar,
and sural); (b) quantitative sensory testing to measure sensory threshold for vibration,
warm and cold sensation (WS-CS), heat and cold-induced pain; and (c) blood sample
analysis to evaluate glucose and insulin levels and calculate the quantitative insulin-sensi-
tivity check index (QUICKI). The obese group showed significantly decreased compound
muscle action potential amplitude of tibial and peroneal nerves and decreased sensory
action potential amplitude of all nerves. Most of the sensory thresholds were altered in
obese patients. Insulin serum levels were significantly increased while QUICKI decreased
in obese patients. WS and CS from the index and little fingers and WS from the big toe
significantly correlated with QUICKI. Thermal and pain thresholds from the index and
thermal thresholds from the little finger correlated with QUICKI values. The non-diabetic
obese patients showed a subclinical involvement of different diameter sensory fibers.
Such impairment was related to hyperinsulinemia and insulin sensitivity. The increase in
sensory threshold of obese patients might be due to a metabolic alteration, potentially
leading to a future clinical neuropathy.
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Introduction
The thickness of the subcutaneous tissues in obese
people has been held to account for the reduction in
amplitude of sensory/mixed nerve responses when
nerve conduction studies are performed using surface
recording and percutaneous stimulation (Dumitru, 1995;
Dorfman and Robinson, 1997; Buschbacher, 1998).
Although this interpretation seems reasonable, obese
people have also an increased risk for various metabolic
disorders, including impaired response to insulin in
absence of increased blood glucose levels (Peters,
2000; Novella et al., 2001). In fact, insulin-sensitivity in
non-diabetic persons is inversely correlated to body
mass index (BMI) (Kahn et al., 1993), suggesting that
obese patients develop increased insulin resistance.
Nevertheless, to our knowledge, reports on nerve con-
duction studies in obesity lack any comments about
these metabolic abnormalities.
In this prospective study, we had two aims to (1)
investigate motor (MNCS) and sensory (SNCS) nerve
conduction in a sample of non-diabetic obese patients
without symptoms of neuropathy and (2) examine the
relevance of the relationship between obesity and low-
insulin sensitivity for the development of a subclinical
peripheral nerve damage.
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Materials and Methods
Twenty-one non-diabetic obese patients (mean
age 38.95 years, range 20–60 years) with normal
Achilles reflexes and sensation and without symp-
toms of peripheral nerve or root involvement and 20
age- and sex-matched controls (mean age 37.95
years, range 29–48 years) were recruited. Mean BMI
was 41.06  4.74 and 22.71  2.88, respectively
(p  0.0001). The mean height of the obese patients
was 165.9  10.6 cm (range 150–188 cm) and that of
the controls was 170.8  10 cm (range 155–182 cm)
(p ¼ 0.67). Exclusion criteria included other neurologi-
cal or neuromuscular conditions, drugs, diabetes, thy-
roid disease, alcoholism, root lesions, symptoms of
sensory dysfunction, and familial history of neuropa-
thy. Diabetes was excluded according to American
Diabetes Association criteria (American Diabetes
Association, 2003), which defines a plasmatic basal
glucose level higher than 126 mg/dL as a reliable indi-
cator of diabetes. The study was approved by the local
Ethical Committee.
A conventional neurographic study was performed
to measure MNCS and/or SNCS in median, ulnar, per-
oneal, tibial, and sural nerves. SNCS was performed
orthodromically for ulnar and median nerves, anti-dro-
mically for the sural nerve, using disposable surface
electrodes (Neuroline 700 10-SC). The distance
between the stimulating electrode and G1 was kept
constant in all the subjects. For MNCS, the onset
latency, amplitude, and nerve conduction velocity
were measured. For SNCS, the onset latency and
peak to peak amplitude were measured. Skin surface
temperature was measured over the dorsum of the
hand and foot. The limb was warmed with a hair-
dryer if below 32C. Filter settings were 2 Hz to
10 kHz and 20 Hz to 2 kHz, respectively, for motor
and sensory recordings.
A computerized quantitative device (Medoc Ltd;
TSA II-2001 and VSA-3000) was used to test the
thresholds for vibratory sensation (Vib), warm and
cold sensation (WS-CS), and heat- and cold-induced
pain (HP-CP) (Dyck et al., 1993; Shy et al., 2003;
Chong and Cros, 2004). The TSA-II-Neuro Sensory
Analyzer and VSA-3000 Vibratory Sensory Analyzer
are computerized non-invasive diagnostic tools for the
quantitative assessment, respectively, of small caliber
A-Delta/C and large caliber A-Beta sensory fiber dys-
function. A small thermal probe capable of heating or
cooling was attached to the patient’s skin. VSA-3000
measured the sensory threshold to vibration stimuli,
between 0.1 and 130 m/s, by means of a vibratory
platform on both hand and foot. According to the
method of limits for both thermal and vibratory stimu-
lation, the stimulus that progressively increases in
intensity was halted by the subject with a simple
push-button response as soon as sensation was per-
ceived (Dyck et al., 1993; Shy et al., 2003). The analy-
sis of HP and CP is not a pain-tolerance test. The
patient is instructed to press the button when thermal
sensation becomes unpleasant.
All subjects performed a sensitivity test composed
of CS (range 32–0C), WS (range 32–50C), CP (range
32–0C), HP (range 32–50C), and vibratory sensation,
six stimuli each and with a 4-s inter-stimulus interval
to avoid adaptation. Thresholds were calculated on the
mean value of each single test. Every test was per-
formed on the plantar side of the big toe, hand palmar
index, and little finger bilaterally.
Insulin resistance was determined in all subjects with
the quantitative insulin-sensitivity check index (QUICKI)
(Katz et al., 2000), calculatedmeasuring the fasting insulin
and glucose serum levels at baseline condition. This
method was previously validated with the in vivo gold
standard technique for insulin sensitivity, the hyperinsuli-
nemic euglycemic clamp (Abbasi and Reaven, 2002).
Statistical analysis
Descriptive statistics (mean values  SD) were
used. Mann–Whitney U-test was used to compare
the neurophysiological data in obese people and con-
trol group; p < 0.05 was the limit for a significant
difference. The correlations between the neurophysio-
logical data and BMI or QUICKI were tested by means
of Pearson’s regression analysis. The statistical pro-
gram used was STATVIEW 5.0 (SAS Institute, Inc).
Results
Tables 1 and 2 summarize the findings for MNCS
and SNCS study and for sensory thresholds, respec-
tively, in obese patients and controls; the difference
between the two groups is also reported (p value).
Obese patients did not show a difference in glucose
levels with respect to normal subjects but showed a
significant increase in insulin serum levels and
decreased QUICKI values as described in Table 3.
BMI was significantly correlated to QUICKI
(r ¼ 0.63, p < 0.0001). BMI highly correlated with
motor and sensory latencies (M-ulnar nerve: r ¼
0.40, p ¼ 0.0002; M-tibial nerve: r ¼ 0.36,
p ¼ 0.001; M-peronal nerve: r ¼ 0.50, p < 0.0001;
SAP median nerve: r ¼ 0.31, p ¼ 0.008; SAP ulnar
nerve: r ¼ 0.43, p < 0.0001; and sural nerve: r ¼
0.33, p ¼ 0.002) and namely to sensory response
amplitudes (median nerve: r ¼ 0.59, p < 0.0001;
ulnar nerve: r ¼ 0.45, p < 0.0001; and sural nerve:
r ¼ 0.55, p < 0.0001). No correlation was found
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between compound muscle action potential–sensory
nerve action potential parameters and QUICKI index.
Vibratory thresholds tended to be related to BMI
but without reaching statistical significance (vibratory
thresholds from index and little finger: r ¼ þ0.40,
p ¼ 0.02 and r ¼ þ0.37, p ¼ 0.02, respectively). Any
of the thermal and pain thresholds significantly corre-
lated to BMI. Conversely, most of the thermal thres-
holds significantly correlated to QUICKI values (CS
from index and little finger: r ¼ þ0.50, p ¼ 0.004 and
r ¼ þ0.42, p ¼ 0.009, respectively; WS from index
and little finger: r ¼ 0.43, p ¼ 0.01 and r ¼ 0.46,
p ¼ 0.003, respectively; and WS from allux r ¼ 0.47,
p ¼ 0.002). Pain threshold did not show correlation
with QUICKI.
Discussion
This study confirms previous reports documenting
the reduction of motor and sensory nerve-response
amplitudes in obese people and its correlation to BMI
(Dumitru, 1995; Dorfman and Robinson, 1997;
Table 1. Comparison of the MNCS and SNCS in controls and obese patients (Mann^Whitney U-test).
Controls Obese patients p
MNCS
Median latency 2.89  0.43 2.88  0.33 0.82
Median amplitude 16.5  3.8 15.9  3.0 0.49
Median CV 58  3.9 59.1  3.8 0.28
Ulnar latency 2.44  0.49 2.11  0.27 0.011
Ulnar amplitude 17.2  2.7 15.7  2.5 0.043
Ulnar CV 61.1  4.9 61.9  3.8 0.52
Tibial latency 3.92  0.71 3.44  0.76 0.043
Tibial amplitude 24.9  6.2 15.6  4.9 <0.0001
Tibial CV 49.6  4.5 50.9  4.4 0.31
Peroneal latency 3.82  0.74 3.15  0.56 0.002
Peroneal amplitude 11.0  2.7 9.0  2.8 0.025
Peroneal CV 50.4  2.9 53.6  3.7 0.004
SNCS
Median latency 2.23  0.3 2.11  0.28 0.09
Median amplitude 27.7  9.5 18.6  3.9 <0.0001
Median CV 56.9  5.0 58.9  6.1 0.16
Ulnar latency 1.89  0.33 1.64  0.17 0.0005
Ulnar amplitude 21.2  14.1 10.5  2.8 0.002
Ulnar CV 58.4  5.4 62.2  4.6 0.002
Sural latency 1.9  0.44 1.72  0.42 0.12
Sural amplitude 33.2  10.9 21.4  7.8 <0.0001
Sural CV 58.4  5.6 61.8  6.4 0.031
CV, conduction velocity; MNCS, motor nerve conduction study; SNCS, sensory nerve conduction study.
Table 2. Comparison of the sensory threshold findings in controls and obese patients (Mann^WhitneyU-test).
Controls Obese patients p
Vibratory threshold
Index finger 1.29  0.61 2.66  4.25 0.71
Little finger 1.32  0.68 2.10  2.7 0.87
Big toe 3.1  1.45 5.6  5.34 0.10
Thermal and pain threshold
CS index finger 28.5  1.9 28.6  3.1 0.9
WS index finger 35.1  1.7 36.6  3.8 0.17
CP index finger 20.5  5.1 12.8  10.2 0.004
HP index finger 42.6  3.6 46.4  3.6 0.002
CS little finger 27.6  2.2 27.5  3.7 0.56
WS little finger 35.7  1.8 37.7  3.3 0.02
CP little finger 19.3  6.0 13.1  10.1 0.021
HP little finger 43.3  3.5 46.2  3.9 0.016
CS big toe 25.6  3.0 26.1  3.0 0.41
WS big toe 40.2  3.8 41.5  3.7 0.11
CP big toe 17.5  5.4 13.5  9.8 0.12
HP big toe 46.9  2.7 48.1  3.0 0.18
CP, cold pain; CS, cold sensation; HP, heat pain;WS, warm sensation.
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Buschbacher, 1998). In fact, the thicker subcutaneous
layer can dampen the amplitude of the nerve response
when surface recording and percutaneous stimulation
are used. The deeper location of the tibial nerve could
account for themore consistent decrease in amplitude of
this nerve in obese subjects (Buschbacher, 1998). We
also found a significant reduction in some latency times
of motor and sensory responses, according with the data
by Buschbacher (1998). However, the relationship that
we have confirmed between reduced motor/sensory
amplitudes and BMI masks possible damage because
of the metabolic derangement related to obesity.
Our study, in fact, showed a subclinical involve-
ment also of different diameter sensory fibers in
obese people: the HP thresholds from the index and
little finger and the WS from the little finger were
increased, while CP threshold from the upper limb
districts was highly decreased. Such significant impair-
ment of the thermal threshold was detected exclu-
sively at the upper limb in contrast with the concept
of a length-dependent affection in early neuropathy
cases. It must be underlined that the quantitative com-
puterized sensory threshold test was demonstrated to
be more reliable if detected at the upper limb rather
than at the lower limb (Bravenboer et al., 1992).
The alteration of the thermal thresholds was not
related to BMI, thus excluding an effect because of
excessive weight. We then tried to find an alternative
explanation, exploring the metabolic disorders linked to
obesity. The key finding of the present study was the
apparent exclusive relationship between thermal sen-
sory thresholdwith hyperinsulinemia and reduced insulin
sensitivity, data in favor of an initial involvement of the
small nerve fibers. To our knowledge, the literature to
date lacks any pathological evidence that obesity alone
may cause neuropathy. Conversely, the relationship
between obesity and impaired glycemic control is well
known (Kahn et al., 1993). Recent studies indicate that
abnormal increase in glucose is associated with a major
risk of end-organ injury, including neuropathy (Feldman,
2003), and that impaired glucose tolerance is a causative
factor in sensory neuropathy (Novella et al., 2001;
Russell and Feldman, 2001; Singleton et al., 2001). The
neuropathy associated with impaired glucose tolerance
is milder than the neuropathy associated with diabetes.
Small nerve fibers are prominently affected and may be
the earliest detectable sign of neuropathy in glucose
dysmetabolism (Sumner et al., 2003).
In our sample of obese patients, blood glucose
was in the normal range, but patients showed hyper-
insulinemia and low-insulin sensitivity as documented
by the decreased values of QUICKI. This parameter
has been considered more sensitive than plasma insu-
lin levels in predicting the onset of type 2 diabetes in
obese subjects (Vanhala et al., 2002). The possible
neurogenic impairment expressed by the altered sen-
sory threshold was independent from glucose levels
but related to hyperinsulinemia and insulin sensitivity.
It follows that the increase in the sensory threshold
demonstrated in some obese people might be due to a
specific metabolic alteration, potentially leading to a
future clinical neuropathy.
Our data also indicate that some nerve fibers
might be more susceptible to damage than others, in
particular, the small caliber or amyelinated fibers, while
others with diameters large enough to sustain the
normal conduction velocities may be spared. In this
regard, we cannot exclude that the impaired insulin,
as well as the altered glucose metabolism, may act on
the Naþ channels of the nodes of Ranvier of some
fibers composing the nerve, disrupting their function
(Brismar et al., 1987; Brismar, 1993).
In conclusion, our study, although conducted in a
small sample of patients, documents subclinical per-
ipheral nerve impairment in obesity. The possible inter-
pretations of the derangement of some nerve fibers
overcome the relationship already demonstrated
between obesity and hyperglycemia or diabetes. In
fact, the choice of the patients was very selective, to
attribute a potential pathogenetic value to a metabolic
alteration typical of the obese patients, represented by
the reduced insulin sensitivity.
Further experimental studies based on a larger
sample of obese patients, more accurate neurophysio-
logical (i.e., near-nerve recording) and neuropathologi-
cal (i.e., intraepidermal nerve fibers investigation)
techniques, as well as animal models of obesity,
would provide stronger support for the role of low-
insulin sensitivity as a risk factor for axonal impairment
in obesity.
Table 3. Comparison of the metabolic findings in controls and obese patients (Mann^Whitney U-test).
Controls Obese patients p
Glucose levels (mg/dL) 88.6  13.4 86.6  8.2 NS
Insulin levels (mU/mL) 5.7  2.0 12.0  4.1 <0.0001
QUICKI index 0.378  0.032 0.335  0.019 <0.0001
NS, not significant ; QUICKI, quantitative insulin-sensitivity check index.
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